Sharemaestro company-news research for Ligand Pharmaceuticals Incorporated (LGND), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Measured evidence
Company news sentiment
LGND news sentiment
Ligand Pharmaceuticals Incorporated
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone63Neutral is 50
Constructive news tone
52/100 evidence confidence
100% direct company focus
2 current stories across 1 publishers
Current company news
News confirmed by price
Constructive news tone is drawn from 2 fresh independent stories, including 2 company-specific items across 1 publishers.
Latest source headline Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates finance.yahoo.com · 10 Aug 2026 20:12What supports the read
2 current stories are mapped specifically to LGND.
Cross-story agreement is 96/100, indicating a comparatively coherent tape.
Constructive news tone is being confirmed by positive weekly price action.
What tempers the read
Only 1 publisher currently contribute to the measured read.
63/100
Weighted toneConstructive news tone
52/100
Evidence confidencebuilding confidence
100%/100
Company focus2 direct stories
96/100
Evidence agreement4/100 dispersion
News history
Tone and story flow over 21 days
23 Jul02 Aug12 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth25
2.0 effective storiesSource breadth20
1 independent publishersDirect relevance100
company-specific evidence shareFreshness66
recency-weighted evidenceAgreement96
cross-story consistencySource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Constructive news tone is being confirmed by positive weekly price action.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
Sentiment confirms active trendPositive but stretched
News subjects
What is shaping the score
Deals and strategy821 stories · 50%
Earnings741 stories · 50%
Source mix
Where the evidence comes from
finance.yahoo.com782 stories · 100%
Recurring subjects
Subjects appearing most often
M A1Institutional Investors1Financial Results1Fda Approval1Earnings Per Share1Earnings1Debt Financing1Clinical Trials1Cardiovascular1Biotech1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#174Tone
finance.yahoo.comDirect company coverage
Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
Orchestra BioMed Holdings, Inc. The BACKBEAT global pivotal trial ("BACKBEAT Trial"), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met. Virtue pivotal trial is advancing with further site activations and patient enrollments. $110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand. Company to host R&D Day on November
BiotechCardiovascularClinical TrialsFda ApprovalFinancial ResultsInstitutional Investors
- Published
- 10 Aug 2026 20:12
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#282Tone
finance.yahoo.comDirect company coverage
LGND: XOMA Acquisition Closed
By John Vandermosten, CFA NASDAQ: LGND READ THE FULL LGND RESEARCH NOTE Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported second quarter 2026 results boasting total revenue and income of $63.7 million, a 34% year over year increase. Adjusted core earnings per share (EPS) of $2.37 were also impressive, rising 48%. By line item, royalties rose 32%, and contract revenue increased by 161%. Captisol was the odd man out, with a revenue decline of 4% due to timing of customer orders. Since Ligand's May financial update, the company has executed a $700 million convertible debt financing and closed
AcquisitionBalance SheetDebt FinancingEarningsEarnings Per ShareM A
- Published
- 10 Aug 2026 09:27
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.